 |
|
|
 |
|
|
|
Healthcare Group – Equity Research
 Corporate Finance
- Public offerings, Private Equity, Financial Advisory
|
Advantages of Research Driven Model
| Increased Profile for Covered Companies with Investors |
Respected, stable research team
Frequent analyst interaction with client management teams
Published research distribution to leading industry investors
|
 |
| Extensive Due Diligence & Superior Industry Expertise |
Early recognition of industry trends and emerging leaders
Insightful investment recommendations
Alignment of investor expectations with prospects of covered companies
|
|
| Timely and Effective Communication with Investment Community |
Morning meeting comments, company reports, industry overviews
Periodic coordinated meetings for corporate clients with key institutional investors
|
|
Research Coverage
|
| Matthew L. Kaplan |
| Drug Delivery |
- Antares Pharma Inc. (AIS)
- Aradigm Corp. (ARDM)
- Flamel Technologies SA (FLML)
- Sonus Pharmaceuticals Inc. (SNUS)
|
| Therapeutics |
- Cell Therapeutics Inc. (CTIC)
- Encysive Pharmaceuticals Inc. (ENCY)
- IsoRay (ISR)
- Keryx Biopharmaceuticals Inc. (KERX)
- Osteologix (OLGX)
- Repros Therapeutics Inc. (RPRX)
- United Therapeutics Corp. (UTHR)
|
| Jeff Nelson |
| Platform Technologies |
- CombinatoRX, Inc. (CRXX)
- Micromet, Inc. (MITI)
- Xoma, Inc (XOMA)
- Covance Inc. (CVD)
- Icon Plc (IDLR)
- Kendle International (KNDL)
- Pharmaceutical Product Development (PPDI)
- Pharma Net Development Group (PDGI)
- Parexel International Corp (PRXL)
|
|
| Juan F. Sanchez, M.D. |
| CNS |
- Avigen (AVGN)
- Chelsea Therapeutics International, Ltd. (CHTP)
- Corcept Therapeutics Inc. (CORT)
- Cypress Bioscience Inc. (CYPB)
- Harris & Harris Group (TINY)
- Indevus Pharmaceuticals Inc. (IDEV)
- Javelin Pharmaceuticals Inc. (JAV)
- Micrus Endovascular Corp. (MEND)
- NEUROMetrix Inc. (NURO)
- XenoPort, Inc. (XNPT)
- XTL Biopharmaceuticals Ltd. (XTLB)
|
|
Equity Research – Life Sciences
Matthew L. Kaplan
Managing Director |
- Focus on therapeutic companies, cardiovascular and drug delivery
- Thirteen years as biotechnology analyst at PZ & Co, Evolution Capital and The Carson Group
- Six years of research experience with the Albert Einstein College of Medicine/Montefiore Hospital Department of Cardiology
- Co-author of numerous articles on gene regulation in the heart
- BS in Biology, University of Michigan; Cellular & Molecular Biology studies at Columbia
|
|
Jeff Nelson
Vice President |
- Focus on immunology, antibody therapeutics and platform technology companies.
- Three years experience in the generic pharmaceutical industry at the Arrow Group and Cobalt Pharmaceuticals.
- Regulatory, manufacturing and strategic consultant for several IND and discovery stage biotech start-up companies.
- BA in Economics, Brandeis University
|
|
Juan Sanchez, M.D.
Vice President |
- Focus on central nervous system therapeutics and nanotechnology
- Previous experience in oncology marketing at Bristol Myers Squibb; Post-genomic strategy planning, Office of the Vice Provost, Columbia University
- Five years in clinical medical practice
- MIA, Columbia University; MBA, University of Los Andes; MD, Javeriana University
|
|
|
|
|
|
